CompletedPhase 2NCT01904682
Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Traws Pharma, Inc.
- Principal Investigator
- Steven M. Fruchtman, MDTraws Pharma, Inc.
- Intervention
- Oral rigosertib(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2021
Study locations (14)
- Stanford University School of Medicine, Stanford, California, United States
- Anschutz Cancer Pavilion University of Colorado, Aurora, Colorado, United States
- Washington Cancer Institute at Medstar Washington Hospital Center, Washington D.C., District of Columbia, United States
- The University of Chicago, Chicago, Illinois, United States
- Greenbaum Cancer Center University of Maryland, Baltimore, Maryland, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Mount Sinai Medical Center, New York, New York, United States
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Hôpital Saint-Louis, Service d'Hématologie, Paris, IDF, France
- Universitätsklinikum Köln, Cologne, North Rhine-Westphalia, Germany
- Heinrich Heine Universität, Düsseldorf, North Rhine-Westphalia, Germany
- Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Saxony, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01904682 on ClinicalTrials.govOther trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06303193Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT07422480A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood TransfusionsTakeda
- RECRUITINGNANCT07500753A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals
- RECRUITINGPHASE1NCT07107126Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromesRemedy Plan, Inc.
- RECRUITINGPHASE1NCT07270978Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDSUniversity of Virginia
- RECRUITINGNANCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisHospices Civils de Lyon
- RECRUITINGPHASE2NCT07228273Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaOHSU Knight Cancer Institute